CA 12-5 bei Karzinomen des Verdauungstraktes: Ein Vergleich mit CA 19-9 und CEA bei Karzinomen des Pankreas und Kolon

Autor:	U. Klapdor, M. Dallek, H. Greten, Hans Schreiber, M. Bahlo, R. Klapdor, H. van Ackeren, B. Kremer
Rok vydání:	2008
Předmět:	medicine.medical_specialty biology business.industry Cancer General Medicine medicine.disease Gastroenterology medicine.anatomical_structure Carcinoembryonic antigen Internal medicine medicine biology.protein Adenocarcinoma Acute pancreatitis Pancreatitis CA19-9 Large intestine Pancreas business
Zdroj:	DMW - Deutsche Medizinische Wochenschrift. 109:1949-1954
ISSN:	1439-4413 0012-0472
Popis:	In 42 control subjects and 134 patients with benign or malignant disease of the pancreas or large intestine, the recently produced tumour-associated antigen CA 12-5 was determined together with CEA and CA 19-9. Only 4% of controls and patients with benign disease (except those with acute pancreatitis) had CA 12-5 values above 35 U/ml, compared with 60% of patients with pancreas carcinoma and 21% with colon carcinoma. For the former (pancreas carcinoma) there was also a good correlation to stage of tumour (0 of 6 tumours stage TxN0M0, 7 of 11 TxN1M0, 16 of 20 TxN1M1 greater than 35 U/ml) and progression of the malignancy. Simultaneous determination of all three antigens increased the rate of tumour-marker positive patients from 87% (CA 19-9) to 92% for pancreas carcinoma and from 25% (CEA) to 51% for colon carcinoma.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9eede1310e159e1ddfb41690d3b2dc07 https://doi.org/10.1055/s-2008-1069483 Zobrazit plný text záznamu